More than 8,000 cases of gynecomastia from the antipsychotic risperidone (brand name Risperdal) were reported in men aged 45 to 85 from the year 2001 to the year 2011. The cases were identified in a medical study conducted to better understand the side effects of Risperdal among the male population, including unwanted breast tissue growth.
Studies have linked Risperdal to gynecomastia breast tissue growth for years, and the prevalence of the antipsychotic drug in foster homes has doctors concerned of the risks facing young boys who are given Risperdal to treat symptoms of bipolar disorder and ADHD. As many as 25% of cases of gynecomastia in boys could be due to drug use, including Risperdal.
An increasing number of Risperdal lawsuits have been filed by patients alleging that the drug caused gynecomastia in boys and male adolescents. As of January 2015, more than 1,000 lawsuits have been consolidated in one state, all alleging that Risperdal led to breast tissue development in boys.